Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

被引:0
|
作者
Gui-mei Yang
Fu-yun Tian
Yan-wen Shen
Chuan-yan Yang
Hui Yuan
Ping Li
Zhao-bing Gao
机构
[1] Zunyi Medical University,School of Pharmacy
[2] Shanghai Institute of Materia Medica,Zhongshan Institute for Drug Discovery
[3] Chinese Academy of Sciences,Center for Neurological and Psychiatric Research and Drug Discovery
[4] Shanghai Institute of Materia Medica,Department of Pediatrics
[5] Chinese Academy of Sciences,Department of Pediatric neurology
[6] The First Medical Center of PLA General Hospital,School of Basic Medicine and Clinical Pharmacy
[7] Children’s Hospital of Fudan university at Xiamen,School of Pharmaceutical Sciences
[8] China Pharmaceutical University,undefined
[9] Southern Medical University,undefined
来源
Acta Pharmacologica Sinica | 2023年 / 44卷
关键词
developmental and epileptic encephalopathy (DEE); KCNQ2 pore mutations; retigabine (RTG); pynegabine (HN37); XEN1101; electrophysiology;
D O I
暂无
中图分类号
学科分类号
摘要
Mutations in the KCNQ2 gene encoding KV7.2 subunit that mediates neuronal M-current cause a severe form of developmental and epileptic encephalopathy (DEE). Electrophysiological evaluation of KCNQ2 mutations has been proved clinically useful in improving outcome prediction and choosing rational anti-seizure medications (ASMs). In this study we described the clinical characteristics, electrophysiological phenotypes and the in vitro response to KCNQ openers of five KCNQ2 pore mutations (V250A, N258Y, H260P, A265T and G290S) from seven patients diagnosed with KCNQ2-DEE. The KCNQ2 variants were transfected into Chinese hamster ovary (CHO) cells alone, in combination with KCNQ3 (1:1) or with wild-type KCNQ2 (KCNQ2-WT) and KCNQ3 in a ratio of 1:1:2, respectively. Their expression and electrophysiological function were assessed. When transfected alone or in combination with KCNQ3, none of these mutations affected the membrane expression of KCNQ2, but most failed to induce a potassium current except A265T, in which trace currents were observed when co-transfected with KCNQ3. When co-expressed with KCNQ2-WT and KCNQ3 (1:1:2), the currents at 0 mV of these mutations were decreased by 30%-70% compared to the KCNQ2/3 channel, which could be significantly rescued by applying KCNQ openers including the approved antiepileptic drug retigabine (RTG, 10 μM), as well as two candidates subjected to clinical trials, pynegabine (HN37, 1 μM) and XEN1101 (1 μM). These newly identified pathologic variants enrich the KCNQ2-DEE mutation hotspots in the pore-forming domain. This electrophysiological study provides a rational basis for personalized therapy with KCNQ openers in DEE patients carrying loss-of-function (LOF) mutations in KCNQ2.
引用
收藏
页码:1589 / 1599
页数:10
相关论文
共 50 条
  • [21] Identifying mutation hotspots reveals pathogenetic mechanisms of KCNQ2 epileptic encephalopathy
    Jiaren Zhang
    Eung Chang Kim
    Congcong Chen
    Erik Procko
    Shashank Pant
    Kin Lam
    Jaimin Patel
    Rebecca Choi
    Mary Hong
    Dhruv Joshi
    Eric Bolton
    Emad Tajkhorshid
    Hee Jung Chung
    Scientific Reports, 10
  • [22] Identifying mutation hotspots reveals pathogenetic mechanisms of KCNQ2 epileptic encephalopathy
    Zhang, Jiaren
    Kim, Eung Chang
    Chen, Congcong
    Procko, Erik
    Pant, Shashank
    Lam, Kin
    Patel, Jaimin
    Choi, Rebecca
    Hong, Mary
    Joshi, Dhruv
    Bolton, Eric
    Tajkhorshid, Emad
    Chung, Hee Jung
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Patient outcomes in KCNQ2 developmental and epileptic encephalopathy: Systematic literature review
    Maclaine, G.
    Potashman, M. H.
    Pawar, D.
    Sharma, S.
    Rudell, K.
    Lerner, J.
    Coric, V.
    Berg, A. T.
    Millichap, J.
    L'Italien, G.
    EPILEPSIA, 2024, 65 : 374 - 375
  • [24] MUTATIONS IN KCNQ2 ARE ASSOCIATED WITH SEVERE NEONATAL EPILEPSY
    Suls, A.
    Audenaert, D.
    Van Dyck, T.
    Weckhuysen, S.
    Baets, J.
    Hasaerts, D.
    Jansen, A.
    Lagae, L.
    Jordanova, A.
    De Jonghe, P.
    EPILEPSIA, 2010, 51 : 141 - 141
  • [25] Skeletal anomaly and opisthotonus in early-onset epileptic encephalopathy with KCNQ2 abnormality
    Kawano, Osamu
    Saito, Takashi
    Sumitomo, Noriko
    Takeshita, Eri
    Shimizu-Motohashi, Yuko
    Nakagawa, Eiji
    Mizuma, Kanako
    Tanifuji, Sachiko
    Itai, Toshiyuki
    Miyatake, Satoko
    Matsumoto, Naomichi
    Takahashi, Yuji
    Mizusawa, Hidehiro
    Sasaki, Masayuki
    BRAIN & DEVELOPMENT, 2023, 45 (04): : 231 - 236
  • [26] Regional Specificity Of KCNQ2 Missense Variants Causing Benign Or Epileptic Encephalopathy Phenotype
    Ishii, A.
    Goto, A.
    Shibata, M.
    Ihara, Y.
    Hirose, S.
    EPILEPSIA, 2019, 60 : 226 - 227
  • [27] Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review
    Chen, Jun
    Tao, Qiuji
    Fan, Lijuan
    Shen, Yajun
    Liu, Jinfeng
    Luo, Huan
    Yang, Zuozhen
    Liang, Mengmeng
    Gan, Jing
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2022, 10 (10):
  • [28] A De Novo KCNQ2 Genomic Variant in an Infant with Early Infantile Epileptic Encephalopathy
    del Rosario Velez-Galarraga, Maria
    Coronel, Melissa
    Vaca, Richard
    Baquerizo, Arianna
    Sanchez-Carpintero, Rocio
    JOURNAL OF PEDIATRIC EPILEPSY, 2020, 9 (01) : 13 - 17
  • [29] Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy
    Ye, Jia
    Tang, Siyang
    Miao, Pu
    Gong, Zhefeng
    Shu, Qiang
    Feng, Jianhua
    Li, Yuezhou
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16
  • [30] Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy
    Goto, Ayako
    Ishii, Atsushi
    Shibata, Mami
    Ihara, Yukiko
    Cooper, Edward C.
    Hirose, Shinichi
    EPILEPSIA, 2019, 60 (09) : 1870 - 1880